10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2011 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2011 10-K (Filed: Feb 21, 2012) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | |
| Cash Flow From (Used in) Operating Activities: | |||
| Net earnings | $ 4,728,449 | 4,626,172 | 5,745,838 |
| Adjustments to reconcile earnings to net cash from operating activities | |||
| Depreciation | 1,395,371 | 1,207,450 | 1,210,977 |
| Amortization of intangible assets | 1,648,523 | 1,416,855 | 878,533 |
| Derecognition of a contingent liability associated with the conclusion of the TAP Pharmaceutical Products Inc. joint venture | (797,130) | ||
| Share-based compensation | 382,602 | 387,183 | 366,357 |
| Acquired in-process and collaborations research and development | 672,500 | 313,200 | 170,000 |
| Investing and financing (gains) losses, net | 141,565 | 126,337 | 41,967 |
| Trade receivables | (670,152) | (394,665) | (387,749) |
| Inventories | (129,621) | 139,857 | 230,555 |
| Prepaid expenses and other assets | 413,266 | 553,145 | (386,889) |
| Trade accounts payable and other liabilities | 1,789,652 | 572,533 | (374,715) |
| Income taxes | (1,402,078) | (212,086) | 577,416 |
| Net Cash From Operating Activities | 8,970,077 | 8,735,981 | 7,275,160 |
| Cash Flow From (Used in) Investing Activities: | |||
| Acquisitions of businesses and technologies, net of cash acquired | (672,500) | (9,433,243) | (2,370,630) |
| Acquisitions of property and equipment | (1,491,500) | (1,015,075) | (1,089,048) |
| Purchases of investment securities | (5,109,987) | (805,932) | (248,970) |
| Proceeds from sales of investment securities | 5,648,720 | 954,361 | 16,306 |
| Release of (deposit of) restricted funds | 1,870,000 | (1,870,000) | |
| Other | 16,099 | (18,426) | (6,368) |
| Net Cash From (Used in) Investing Activities | 260,832 | (12,188,315) | (3,698,710) |
| Cash Flow From (Used in) Financing Activities: | |||
| (Repayments of) proceeds from issuance of short-term debt and other | (1,964,685) | (203,854) | 3,217,331 |
| Proceeds from issuance of long-term debt and debt with maturities over 3 months | 1,000,000 | 4,000,000 | 3,000,000 |
| Repayments of long-term debt and debt with maturities over 3 months | (3,012,426) | (1,673,998) | (2,483,176) |
| Purchases of common shares | (77,007) | (866,825) | (826,345) |
| Proceeds from stock options exercised, including income tax benefit | 968,759 | 328,411 | 508,669 |
| Dividends paid | (2,938,096) | (2,671,475) | (2,414,460) |
| Net Cash (Used in) From Financing Activities | (6,023,455) | (1,087,741) | 1,002,019 |
| Effect of exchange rate changes on cash and cash equivalents | (43,005) | (620,893) | 118,848 |
| Net Increase (Decrease) in Cash and Cash Equivalents | 3,164,449 | (5,160,968) | 4,697,317 |
| Cash and Cash Equivalents, Beginning of Year | 3,648,371 | 8,809,339 | |
| Cash and Cash Equivalents, End of Year | 6,812,820 | 3,648,371 | 8,809,339 |
| Supplemental Cash Flow Information: | |||
| Income taxes paid | 1,781,602 | 809,710 | 635,445 |
| Interest paid | 544,559 | 580,168 | 514,326 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2011 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |